Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03514420 · ClinicalTrials.gov registry record · Phase 2
Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)
A Phase 2 study, sponsored by Akcea Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03514420 is a Phase 2 study that has completed, run by Akcea Therapeutics. The registered enrollment target is 4 participants.
The verdict
NCT03514420, a Phase 2 study, has completed, sponsored by Akcea Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of fasting triglycerides in participants with familial partial lipodystrophy.
Interventions
- DRUG AKCEA-ANGPTL3-LRx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-06-15 |
| Est. Completion | 2019-08-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03514420
The ClinicalTrials.gov registry entry for NCT03514420 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akcea Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AKCEA-ANGPTL3-LRx is the first listed.
NCT03514420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03514420 about?
NCT03514420 is a clinical study titled "Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)". This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of fasting triglycerides in participants with familial partial lipodystrophy.
What is the current status of trial NCT03514420?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2018-06-15. Estimated completion is 2019-08-21.
What interventions are being tested in trial NCT03514420?
The interventions under investigation include: AKCEA-ANGPTL3-LRx (DRUG).
Who is sponsoring clinical trial NCT03514420?
This trial is sponsored by Akcea Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.